몬테 로사 테라퓨틱스(GLUE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.13 (-3.73%), 시가총액 $1.61B, 52주 최저~최고 $3.70 ~ $25.31.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric
몬테 로사 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
몬테 로사 테라퓨틱스의 현재 주가는 $12.13 (-3.73%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
몬테 로사 테라퓨틱스의 시가총액은 약 $1.61B입니다.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively d